IPSC Stock Price, 2 Quote, Chart

Market Summary

USD2.91-0.14

Market Closed

-4.59%

IPSC Stock Price

View Fullscreen

IPSC RSI Chart

IPSC Valuation

Market Cap

188.6M

Price/Earnings (Trailing)

-1.38

Price/Sales (Trailing)

84.39

EV/EBITDA

-1.17

Price/Free Cashflow

-1.85

IPSC Price/Sales (Trailing)

IPSC Profitability

EBT Margin

-6030.96%

Return on Equity

-73.98%

Return on Assets

-37.89%

Free Cashflow Yield

-54.12%

IPSC Fundamentals

IPSC Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

147.06%

Rev. Growth (Qtr)

3.4K%

IPSC Earnings

Earnings (TTM)

-136.7M

Earnings Growth (Yr)

-24.35%

Earnings Growth (Qtr)

-20.41%

Breaking Down IPSC Revenue

Last 30 days

-27.0%

Last 90 days

-30.2%

Trailing 12 Months

-2.6%

How does IPSC drawdown profile look like?

IPSC Financial Health

Current Ratio

9.92

Debt/Equity

0.02

Debt/Cashflow

-23.63

IPSC Investor Care

Shares Dilution (1Y)

1.46%

Diluted EPS (TTM)

-2.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.6M	5.3M	7.4M	2.2M
2022	0	0	0	5.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 2

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	russotti gregory	sold	-15,489	3.0979	-5,000	see remarks
Mar 07, 2024	pfeiffenberger brent	acquired	-	-	17,425	president and ceo
Mar 07, 2024	farid adrienne	acquired	-	-	24,000	chief operations officer
Mar 07, 2024	russotti gregory	acquired	-	-	24,000	see remarks
Mar 07, 2024	carr douglas	acquired	-	-	14,000	svp finance & operations
Mar 07, 2024	levitsky hyam	acquired	-	-	24,000	president of r&d
Mar 07, 2024	farid adrienne	acquired	23,515	1.03	22,831	chief operations officer
Mar 07, 2024	farid adrienne	sold	-117,342	5.1396	-22,831	chief operations officer
Mar 06, 2024	farid adrienne	acquired	31,604	1.03	30,684	chief operations officer
Mar 06, 2024	farid adrienne	sold	-152,340	4.9648	-30,684	chief operations officer

Which funds bought or sold IPSC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	added	723	10,000	10,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-21.69	-4,234	296,412	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-62.51	-3,000	3,000	-%
Apr 17, 2024	FOUNDERS FINANCIAL SECURITIES LLC	unchanged	-	8,600	41,800	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	unchanged	-	67,265	326,939	-%
Apr 05, 2024	GAMMA Investing LLC	added	67.61	480	1,233	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.49	1,495,510	3,733,850	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	84.87	199,754	296,310	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.39	15,277	38,655	-%

Are Funds Buying or Selling IPSC?

Are funds buying IPSC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IPSC

No. of Funds

Unveiling 2's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	bain capital life sciences opportunities iii, lp	6.6%	5,320,331	SC 13G
Apr 22, 2024	boxer capital, llc	5.8%	4,901,603	SC 13G
Apr 18, 2024	casdin capital, llc	6.08%	5,190,506	SC 13G
Apr 08, 2024	casdin capital, llc	4.95%	3,206,380	SC 13D/A
Mar 04, 2024	venrock healthcare capital partners iii, l.p.	5.4%	3,405,133	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	versant venture capital vi, l.p.	19.1%	11,452,014	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	versant venture capital vi, l.p.	19.4%	11,452,014	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of 2

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	SC 13G	Major Ownership Report
Apr 24, 2024	4	Insider Trading
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 22, 2024	SC 13G	Major Ownership Report
Apr 18, 2024	SC 13G	Major Ownership Report
Apr 16, 2024	PRE 14A	PRE 14A
Apr 11, 2024	8-K	Current Report

Peers (Alternatives to 2)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	4.75%	-16.01%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-1.40%	-26.02%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-5.97%	-14.48%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.7B	-7.74%	-29.36%	19.56	3.16	8.87%	75.42%
MID-CAP
APLS	5.3B	396.6M	-18.63%	-42.67%	-10.08	13.43	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-19.13%	-34.68%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-10.25%	-44.07%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-9.17%	305.92%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.15%	24.46%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-59.11%	53.70%	-0.22	2.14	-13.45%	66.37%

2 News

Latest updates

2 Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-100.0%	-	3,486,000	99,000	1,720,000	2,081,500	1,411,000	1,396,000	1,058,000
Operating Expenses	23.1%	44,030,000	35,774,000	35,176,000	33,801,000	33,827,000	33,962,000	32,747,000	38,494,000
S&GA Expenses	-4.4%	8,589,000	8,986,000	8,229,000	8,902,000	8,242,000	8,064,000	8,253,000	7,298,000
EBITDA Margin	-253.7%	-54.21	-15.33	-21.09	-16.95	-20.40	-	-	-
Interest Expenses	-	46,000	-	136,000	404,000	80,000	373,000	330,000	314,000
Income Taxes	-246.8%	-869,000	592,000	950,000	1,208,000	32,000	25,000	18,000	16,000
Earnings Before Taxes	-25.3%	-40,267,000	-32,128,000	-32,341,000	-30,056,000	-31,650,000	-30,724,000	-30,970,000	-37,497,000
EBT Margin	-253.1%	-60.31	-17.08	-23.49	-18.67	-22.00	-	-	-
Net Income	-20.4%	-39,398,000	-32,720,000	-33,291,000	-31,264,000	-31,682,000	-30,749,000	-30,988,000	-37,513,000
Net Income Margin	-250.3%	-61.15	-17.46	-23.91	-18.87	-22.02	-	-	-
Free Cashflow	-60.9%	-27,210,000	-16,914,000	-23,750,000	-34,210,000	-29,175,000	-34,050,000	-36,013,000	82,686,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-9.3%	361	398	417	456	487	512	533	550	437	470	496	107
Current Assets	1.9%	177	174	161	256	320	362	384	365	228	300	403	79.00
Cash Equivalents	-14.4%	47.00	55.00	64.00	87.00	84.00	113	115	128	58.00	103	275	28.00
Net PPE	-12.5%	72.00	82.00	84.00	86.00	83.00	78.00	70.00	65.00	58.00	49.00	34.00	15.00
Liabilities	-1.3%	176	178	170	179	184	182	175	164	41.00	47.00	48.00	33.00
Current Liabilities	-12.7%	18.00	20.00	19.00	28.00	30.00	27.00	22.00	22.00	16.00	20.00	21.00	12.00
Long Term Debt	-	-	-	-	-	4.00	6.00	9.00	10.00	9.00	10.00	10.00	10.00
LT Debt, Non Current	-	-	-	-	-	4.00	6.00	9.00	10.00	9.00	-	-	10.00
Shareholder's Equity	-15.7%	185	219	248	277	303	330	358	387	396	423	448	-
Retained Earnings	-6.4%	-655	-616	-583	-550	-519	-487	-456	-425	-388	-359	-333	-292
Additional Paid-In Capital	0.4%	840	837	832	829	824	821	818	815	785	783	782	218
Shares Outstanding	1.4%	60.00	60.00	59.00	59.00	55.00	58.00	57.00	57.00	58.00	25.00	12.00	7.00
Float	-	-	-	132	-	-	-	368	-	-	-	669	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-92.2%	-26,230	-13,649	-19,250	-29,219	-22,907	-24,238	-25,556	86,753	-24,351	-23,983	-18,489	-22,179	-	-	-
Share Based Compensation	-10.5%	3,562	3,978	3,285	3,797	2,732	2,786	2,771	2,380	1,636	1,220	1,711	95.00	-	-	-
Cashflow From Investing	341.1%	18,603	4,217	6,974	31,338	-4,273	22,664	12,518	-44,037	-20,602	-147,054	-11,648	-119,034	-	-	-
Cashflow From Financing	-218.7%	-356	300	-10,117	448	95.00	137	48.00	26,878	106	-466	224,649	193,485	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IPSC Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Collaboration revenue	$ 2,235	$ 5,199
Operating expenses
Research and development	92,710	97,173
General and administrative	34,706	31,857
In-process research and development	5,000	10,000
Impairment of long-lived assets	16,365
Total operating expenses	148,781	139,030
Loss from operations	(146,546)	(133,831)
Interest expense	(540)	(1,430)
Interest income	12,677	4,420
Other expense	(383)
Total other income (expense)	11,754	2,990
Loss before provision for income taxes	(134,792)	(130,841)
Provision for income taxes	(1,881)	(91)
Net loss	$ (136,673)	$ (130,932)
Net loss per common share Basic (in dollars per share)	$ (2.30)	$ (2.27)
Net loss per common share Diluted (in dollars per share)	$ (2.27)	$ (2.96)
Weighted average common shares outstanding Basic (in shares)	59,314,389	57,755,842
Weighted average common shares outstanding Diluted (in shares)	57,755,842	32,392,554
Other comprehensive loss
Net Income (Loss)	$ (136,673)	$ (130,932)
Unrealized gain (loss) on investments	2,602	(1,786)
Foreign currency translation gain (loss)	(32)	(26)
Comprehensive loss	$ (134,103)	$ (132,744)

IPSC Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 47,324	$ 84,265
Short-term investments	125,414	231,233
Escrow deposits, current		220
Prepaid expenses and other current assets	4,256	4,003
Total current assets	176,994	319,721
Property and equipment, net	71,705	82,785
Operating lease right-of-use assets	20,376	28,945
Restricted cash	1,979	1,979
Long-term investments	89,096	51,854
Security deposits and non-current assets	541	1,260
Total assets	360,691	486,544
Current liabilities
Accounts payable	2,741	5,454
Accrued expenses and other liabilities	10,149	9,841
Deposit liability	584	866
Long-term debt, current		6,502
Deferred revenue, current	4,372	7,154
Total current liabilities	17,846	29,817
Operating lease liability, long term	46,658	38,698
Deposit liability, non-current	56	718
Deferred revenue, non-current	111,381	110,834
Long-term debt, net		3,739
Total liabilities	175,941	183,806
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 125,236,190 shares authorized; 60,335,701 and 58,473,660 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	6	6
Additional paid-in capital	840,407	824,292
Accumulated deficit	(655,771)	(519,098)
Accumulated other comprehensive loss	108	(2,462)
Total stockholders' equity	184,750	302,738
Total liabilities and stockholders' equity	$ 360,691	$ 486,544

About 2

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

CEO	Dr. Gregory Russotti Ph.D.
WEBSITE	centurytx.com
INDUSTRY	Biotechnology
EMPLOYEES	163

2 Frequently Asked Questions

What is the ticker symbol for 2? What does IPSC stand for in stocks?

IPSC is the stock ticker symbol of 2. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 2 (IPSC)?

As of Mon Apr 29 2024, market cap of 2 is 197.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IPSC stock?

You can check IPSC's fair value in chart for subscribers.

What is the fair value of IPSC stock?

You can check IPSC's fair value in chart for subscribers. The fair value of 2 is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 2 is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IPSC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 2 a good stock to buy?

The fair value guage provides a quick view whether IPSC is over valued or under valued. Whether 2 is cheap or expensive depends on the assumptions which impact 2's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IPSC.

What is 2's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, IPSC's PE ratio (Price to Earnings) is -1.45 and Price to Sales (PS) ratio is 88.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IPSC PE ratio will change depending on the future growth rate expectations of investors.